Fosun Pharma's stock surged 5.21% during intraday trading on Wednesday, following the release of its robust 2025 annual results and a proposed final dividend.

The company reported a 21.69% year-on-year increase in net profit attributable to shareholders to RMB 3.37 billion, with revenue rising 1.44% to RMB 41.50 billion. A key growth driver was the performance of its innovative drugs segment, where sales surged 29.59% to RMB 9.89 billion, now accounting for 23.84% of total revenue. Overseas revenue also saw strong growth, climbing 14.87% to RMB 12.98 billion.

Concurrently, the board proposed a final cash dividend of RMB 0.39 per ordinary share for the financial year ended December 31, 2025. The positive financial metrics and shareholder return initiative are seen as the primary catalysts for the significant upward movement in the stock price.